Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.

Nano LIFE, published by World Scientific Publishing Company, is a multidisciplinary journal that delves into the dynamic fields of bioengineering, biomedical engineering, and pharmaceutical science, providing a platform for researchers to disseminate their cutting-edge findings. With an ISSN of 1793-9844 and e-ISSN 1793-9852, this journal emphasizes the significance of nanoscale research in healthcare and technology, positioning itself as a vital resource for professionals and academics alike. Although currently categorized in the Q4 quartile for multiple scientific disciplines in 2023, its unique focus on the intersection of nanotechnology and life sciences aims to elevate the discourse in these rapidly evolving sectors. Researchers can anticipate publishing innovative methodologies and results, contributing to the overall understanding and application of nanotechnology in medicine. Located in Singapore, Nano LIFE not only serves the global research community but also reflects the growing interest in nanotechnology across diverse fields.

Advanced Therapeutics, published by WILEY in the United Kingdom, stands at the forefront of medical and pharmaceutical research, offering invaluable insights from 2018 to 2024. This distinguished journal, with an E-ISSN of 2366-3987, is recognized for its exceptional academic rigor, boasting an impressive array of Q1 categorizations in essential fields such as Biochemistry (medical), Pharmaceutical Science, and Pharmacology. With its strategic focus on interdisciplinary studies and cutting-edge therapeutic developments, Advanced Therapeutics serves as a vital resource for researchers, professionals, and students keen on advancing their knowledge and contributing to the evolving landscape of medicine and genetics. The journal's high Scopus rankings further affirm its impact, with significant placements in multiple categories underscoring the quality of published research. Although the journal operates under a subscription model, its accessibility to high-impact findings ensures that it remains a pivotal platform for innovative discourse in therapeutics.

Current Nanoscience is a prominent journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of nanoscience through the dissemination of high-quality research and review articles. Since its inception in 2006, the journal has provided a platform for innovative studies across a variety of related disciplines, including bioengineering, biomedical engineering, biotechnology, and nanotechnology, reflecting its diverse scope and interdisciplinary nature. With a Q3 ranking in several categories such as Biomedical Engineering and Pharmaceutical Science and a Scopus percentile ranking around the 60th in its field, Current Nanoscience serves as a vital resource for researchers and professionals seeking to stay abreast of the latest developments and breakthroughs. Although it operates without an open access model, the journal maintains a commitment to enhancing accessibility and relevance in the scientific community. The editorial team is focused on publishing articles that address both theoretical and practical aspects of nanoscience, ensuring that the findings contribute to knowledge and innovation in areas critical to technology and healthcare.

BIOMEDICAL MICRODEVICES is a leading journal published by Springer that focuses on the innovative field of microdevices within biomedical engineering. With an ISSN of 1387-2176 and an E-ISSN of 1572-8781, BIOMEDICAL MICRODEVICES offers a prestigious platform for researchers to disseminate their findings from 1998 to 2024, demonstrating a long-standing commitment to advancing knowledge in this critical area. The journal is recognized for its significant contributions, boasting a Q2 ranking in Biomedical Engineering and Nanoscience and Nanotechnology, and a Q3 rank in Molecular Biology. Renowned for its rigorous peer-review process, it is positioned within the top 30% of its field according to Scopus rankings, making it a valuable resource for researchers and practitioners alike. Though it operates under a subscription model, the emphasis on quality and relevance within its scope ensures that BIOMEDICAL MICRODEVICES remains a vital source of cutting-edge research that bridges engineering and biological systems, fostering innovation and collaboration in the pursuit of novel health solutions.

DRUG DELIVERY is a premier academic journal published by TAYLOR & FRANCIS LTD, with a steadfast commitment to advancing research in the fields of medicine and pharmaceutical sciences. As an Open Access journal since 2017, it offers unparalleled accessibility to its high-quality content, making it an invaluable resource for researchers, professionals, and students alike. With an impressive 2023 impact factor, it ranks in the Q1 quartile for both Medicine (miscellaneous) and Pharmaceutical Science, evidencing its significant impact within the scientific community. The journal focuses on innovative drug delivery systems, therapeutics, and methodologies that enhance patient care and treatment options. Based in the United Kingdom, it has evolved since its inception in 1993 to create a richly diverse platform for scholarly dialogue and advancements in the pharmaceutical landscape. Researchers looking to stay at the forefront of drug delivery research will find DRUG DELIVERY an essential companion in their pursuits.

Nanomedicine-Nanotechnology Biology and Medicine is a leading journal published by Elsevier, dedicated to the exploration of innovative applications of nanotechnology in the fields of biology and medicine. With an ISSN of 1549-9634 and an E-ISSN of 1549-9642, this esteemed journal provides a platform for high-quality research, comprehensively covering areas including bioengineering, biomedical engineering, pharmaceutical science, and nanoscience. Notably, it holds a significant position in various categories with a Q2 ranking in multiple disciplines and a prestigious Q1 ranking in Pharmaceutical Science, emphasizing its impact within the scientific community. By facilitating access to cutting-edge studies and advancements, Nanomedicine-Nanotechnology Biology and Medicine serves as an essential resource for researchers, professionals, and students alike, contributing significantly to the ongoing development of nanomedicine and its pivotal role in improving healthcare outcomes. The journal operates without open access; however, it remains committed to disseminating valuable knowledge to a global audience.

The Journal of Experimental Nanoscience, published by Taylor & Francis Ltd, is an esteemed open-access journal dedicated to advancing the field of nanoscience and its applications across various disciplines. Since its establishment, the journal has aimed to provide a comprehensive platform for researchers and professionals to disseminate innovative findings in nanotechnology, bioengineering, and materials science. With an ISSN of 1745-8080 and E-ISSN of 1745-8099, this journal has been pivotal in promoting high-quality research in its converged years from 2006 to 2024. Recognized for its contributions, it currently holds a Q3 ranking in core categories such as Bioengineering, Biomedical Engineering, Materials Science, and Nanoscience and Nanotechnology. Although its H-index is not specified, its Scopus ranks reflect its growing influence, with notable percentiles in various engineering fields. By offering open access since 2016, the Journal of Experimental Nanoscience enhances the accessibility of vital research to a global audience. Researchers, professionals, and students will find this journal an invaluable resource for staying abreast of the latest advancements and breakthroughs in nanoscience.

Biomaterials Science is a premier journal published by the Royal Society of Chemistry that serves as a leading platform for researchers and professionals in the fields of Biomedical Engineering and Materials Science. With an impressive impact factor bolstered by its Q1 quartile ranking in both disciplines, this journal has positioned itself at the forefront of cutting-edge research, showcasing innovative materials and applications that drive advancements in healthcare and technology. Since its inception in 2013, Biomaterials Science has been committed to disseminating high-quality, peer-reviewed articles that promote scientific knowledge and collaboration among academia and industry. With a global readership and a focus on open access, researchers are encouraged to share their findings to facilitate the development of transformative biomaterials and their applications. Join a vibrant community of scholars as we explore the future of biomaterials through this esteemed publication, enhancing both scientific inquiry and practical application.

BioNanoScience is an esteemed academic journal published by SPRINGER, dedicated to the interdisciplinary field of bioengineering and biomedical engineering. With an ISSN of 2191-1630 and an E-ISSN of 2191-1649, the journal has established itself as a significant platform for sharing innovative research and developments in nanotechnology as applied to biomedical contexts. Although it operates under a subscription model, the journal maintains a strong impact within its field, achieving a Q3 quartile ranking in both categories for 2023 and has a solid standing in Scopus rankings, where it ranks #129 out of 303 in Biomedical Engineering and #87 out of 162 in Bioengineering. The journal not only aims to publish high-quality research, but also seeks to foster collaboration between scientists, engineers, and healthcare professionals to address pressing global health challenges through nanotechnology. As an essential resource for researchers, professionals, and students, BioNanoScience continues to contribute to the advancement of knowledge and innovation in bioengineering.